Antithrombotic effect of L-arginine in hypertensive rats

Journal of Physiology and Pharmacology

Volumn 55, Issue 3, 2004, Pages 563-574

  Cylwik, D ^a   Mogielnicki, A ^a   Kramkowski, K ^a   Stokowski, J ^a   Buczko, Wlodzimierz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Haemostasis; L arginine; Rats; Venous thrombosis

Indexed keywords

ARGININE; BETA GLOBULIN; FIBRINOGEN;

ACUTE DRUG ADMINISTRATION; ANIMAL MODEL; ANTITHROMBOTIC EFFECT; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; BLOOD CLOTTING; CHRONIC DRUG ADMINISTRATION; DRUG EFFECT; FIBRINOLYSIS; HEMOSTASIS; HYPERTENSION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RAT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS; THROMBUS WEIGHT; VEIN THROMBOSIS; WEIGHT;

ANIMALS; ARGININE; DISEASE MODELS, ANIMAL; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HYPERTENSION; KIDNEY; MALE; PLATELET AGGREGATION; RATS; RATS, WISTAR; VENOUS THROMBOSIS;

EID: 4844228829     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
2. Palmer RM. The L-arginine:nitric oxide pathway. Curr Opin Nephrol Hypertens 1993; 2: 122-128.
3. Loscalzo J. What we know and don't know about L-arginine and NO. Circulation 2000; 101: 2126-2129.
4. Moncada S. Nitric oxide. J Hypertens 1994; 12 (Suppl. 10): S35-S39.
5. Böger RH, Bode-Böger SM, Mugge A, Kienke S, Brandes R, Dwenger A et al. Supplementation of hypercholesterolacmic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 1995; 117: 273-284.
6. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice. Arterioscler Tromb Vasc Biol 2003; 23: 97-103.
7. Giugliano D, Marfella R, Verrazzo G, Acampora R, Nappo F, Ziccardi P et al. L-arginine for testing endothelium-dependent vascular functions in health and disease. Am J Physiol 1997; 273: E606-E612.
8. Maxwell AJ, Zapien MP, Pearce GL, MacCallum G, Stone PH. Randomized trial of a medical food for the dietary of chronic, stable angina. J Am Coll Cardiol 2002; 39: 37-45.
9. Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K et al. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci 1994; 87: 303-310.
10. Piatti PM, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I et al. Acute intravenous L-arginine infision decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms. Circulation 2003; 107: 429-436.
11. Piatti PM, Monti LD, Valsecchi G, Magni F, Setola E, Marchesi F et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensivity in type 2 diabetic patients. Diabetes Care 2001; 24: 875-880.
12. Adams MR, Forsyth CJ, Jessup W, Robinson J., Celermajer D.S.: Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthly young men. J Am Coll Cardiol 1995; 26: 1054-1061.
13. Gryglewski RJ, Grodzińska L, Kostka-Tra̧bka E, Korbut R, Bieroń K, Goszcz A et al. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien Klin Wochenschr 1996; 108: 111-116.
14. Preli RB, Klein K, Herrington D. Vascular effects of dietary L-arginine supplementation. Atherosclerosis 2002; 162: 1-15.
15. Anfossi G., Russo I., Massucco P., Mattiello L., Perna P., Tassone F., Trovati M.: L-arginine modulates aggregation and intracellular cyclic 3′5′- guanosine monophosphate levels in human platelets: direct effect and interplay with antioxidative thiol agent. Thromb Res 1999; 94: 307-316.
16. Bode-Böger SM, Böger RH, Kienke S, Bohme M, Phivthong-ngam L, Tsikas D, Frölich JC. Chronic dietary supplementation with L-arginine inhibits platelet aggregation and thromboxane A2 synthesis in hypercholesterolaemic rabbits in vivo. Cardiovasc Res 1998; 37: 756-764.
17. 2 formation by L-arginine in vivo and in vitro. Arch Pharmacol 1998; 357: 143-150.
18. Stief TW, Weippert M, Kretschmer V, Renz H. Arginine inhibits hemostasis activation. Thromb Res 2001; 104: 265-274.
19. Chabielska E, Pawlak R, Wollny T, Rółkowski R, Buczko W. Antithrombotic of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action. J Physiol Pharmacol 1999; 50: 99-109.
20. Zatz R.: A low-cost tail-cuff method for the estimation of mean arterial pressure in conscious rats. Lab Anim Sci 1990; 42: 198-201.
21. Reyers I, de Gaetano G, Donati MB. Venostasis-induced thrombosis in rat is not influenced by circulating platelet or leukocyte number. Agents Actions 1989; 28: 137-140.
22. Dejana E, Callioni A, Quintana A, de Gaetano G. Bleeding time in laboratory animals. II-a comparison of different assay conditions in rats. Thromb Res 1979; 15: 191-197.
23. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-138.
24. He S, Bremme K, Blomback M. A labolatory method for determination of overall haemostatic potential in plasma .I. Method design and preliminary results. Thromb Res 1999; 96: 145-156.
25. He S, Antovic A, Blombäck M. A simple and rapid labolatory method for determination of haemostasis potential in plasma.II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103: 355-361.
26. Chabielska E, Pawlak R, Golatowski J, Rółkowski R, Pawlak D, Buczko W. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats. Thromb Res 1998; 90: 271-278.
27. Pawlak R, Chabielska E, Golatowski J, Azzadin A, Buczko W. Nitric oxide and prostacyclin are involved in antithrombotic action of captopril in venous thrombosis in rats. Thromb Haemost 1998; 79: 1208-1212.
28. Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29: 479-485.
29. Mendez JD, Zarzoza E. Inhibition of platelet aggregation by L-arginine and polyamines in alloxan treated rats. Biochem Mol Biol Int 1997; 43: 311-318.
30. Marietta M, Facchinetti F, Neri I, Piccinini F, Volpe A, Torelli G. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res 1997; 88: 229-235.
31. Tsao PS, Theilmeier G, Singer AH, Leung LLK, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14: 1529-1533.
32. Gruszecki M, Rółkowski R, Pawlak R, Buczko W. Propranolol prevents the development of venosus thrombosis in rats by a platelet-dependent mechanism. Pol J Pharmacol 2001; 53: 5-10.
33. Kawabata A, Hata T. Attenuation by prolonged nitric oxide synthase inhibition of the enhancement of fibrinolysis caused by environmental stress in the rat. Br J Pharmacol 1996; 119: 346-350.
34. G-nitroarginine methyl ester on human whole blood coagulation and fibrinolysis. Blood Coagulation and Fibrinolysis 1996; 7: 678-683.
35. Blum A, Hathaway L, Mincemoyer R, Schenke WH, Kirby M, Csako G et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101: 2160-2164.